Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose PR Newswire OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten fatal opioid overdoses in the US invol...
Orexo AB press release ( OTCQX:ORXOY ): Q4 GAAP EPS of -SEK2.67. Revenue of SEK156.1M (+8.4% Y/Y). For further details see: Orexo AB GAAP EPS of -SEK2.67, revenue of SEK156.1M
Orexo Interim Report Q4 2022, incl. Full Year Report PR Newswire UPPSALA, Sweden , Jan. 26, 2023 /PRNewswire/ -- Important steps forward in a challenging environment Q4 2022 highlights Total net revenues of SEK 156.1 m (144.0) EBIT...
Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies PR Newswire Orexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX ® , showing excellent pro...
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the presentations from its KCSA Mental Health Virtual Investor Conference held on...
MORRISTOWN, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Orexo (STO:ORX) (OTCQX:ORXOY) , which develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health, today announced that Nikolaj Sørensen, Pres...
NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Mental Health Virtual Investor Conference to be ...
Orexo AB press release ( OTCQX:ORXOY ): Q3 GAAP EPS of -SEK 0.77. Revenue of SEK 161M (+10.3% Y/Y). EBITDA of -SEK 32.4M, EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 14.3M. For further details see: Orexo AB GAAP EP...
Orexo Interim Report Q3 2022 PR Newswire UPPSALA, Sweden , Nov. 3, 2022 /PRNewswire/ -- Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of SEK 161.0 m (145.9) EBITDA of SEK -32.4 m (-47...
Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD PR Newswire Study evaluating efficacy of MODIA®, a digital therapeutic, in addition to cli...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20 th , 2024. This event is co-sponsored by Zack’s Small Cap Research. ...
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm PR Newswire UPPSALA, Sweden , May 10, 2024 /PRNewswire/ -- On March 28, 2024 , Orexo AB (publ), ("Orexo" or the " Company ") (STO: ORX) (OTCQX: ORXOY) succ...